Venetoclax for arsenic-resistant acute promyelocytic leukaemia

Br J Haematol. 2022 Jun;197(5):e58-e60. doi: 10.1111/bjh.18061. Epub 2022 Feb 17.

Qian Qian Wang¹, Hua-Feng Wang^{1

2

3}, Jian-Zhi Zhao⁴, Hua Naranmandura¹, Jie Jin^{1

2

3}, Hong-Hu Zhu^{1

2

3

5

6}

¹ Department of Haematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, Hangzhou, China.
² Zhejiang Province Key Laboratory of Haematology Oncology Diagnosis and Treatment.
³ Cancer Center, Zhejiang University, Hangzhou, China.
⁴ Department of Haematology, Shaoxing Central Hospital, Shaoxing, China.
⁵ Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, China.
⁶ Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China.

No abstract available

Keywords: acute promyelocytic leukaemia; all-trans retinoic acid; arsenic; mutation; venetoclax.

Publication types